Description: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; bipolar depression and treatment-resistant depression; and brain imaging of beta-amyloid plaques. Its endocrinology products treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. The company's oncology products treat malignant pleural mesothelioma; pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as cardiovascular products, which are used treat erectile dysfunction, benign prostatic hyperplasia, high cholesterol, pulmonary arterial hypertension; reduce thrombotic cardiovascular events; and used as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to improve milk productivity in dairy cows; anticoccidial agents; antibiotics to control enteric infections in calves and swine; products to treat canine separation anxiety; products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections; and other pharmaceutical products to treat staphylococcal and bacterial infections. The company distributes its products through independent wholesale distributors; and directly to pharmacies. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Home Page: www.lilly.com
LLY Technical Analysis
Lilly Corporate Center
Indianapolis,
IN
46285
United States
Phone:
317 276 2000
Officers
Name | Title |
---|---|
Mr. David A. Ricks | Chairman, CEO & Pres |
Ms. Anat Ashkenazi | Sr. VP & CFO |
Dr. Daniel M. Skovronsky M.D., Ph.D. | Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs |
Mr. Diogo Rau | Sr. VP & Chief Information and Digital Officer |
Mr. Jacob S. Van Naarden | Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology |
Mr. Donald A. Zakrowski | Chief Accounting Officer & VP of Fin. |
Mr. Martin Bott MIBS | VP of Fin. & Special Projects |
Ms. Anat Hakim J.D. | Sr. VP, Gen. Counsel & Sec. |
Mr. Alonzo Weems | Sr. VP and Chief Ethics & Compliance Officer |
Ms. Leigh Ann Pusey | Sr. VP of Corp. Affairs & Communications |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 39.0625 |
---|---|
Trailing PE: | 53.2051 |
Price-to-Book MRQ: | 34.0617 |
Price-to-Sales TTM: | 11.699 |
IPO Date: | 1978-01-13 |
Fiscal Year End: | December |
Full Time Employees: | 35000 |